GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: TransCon CNP
Compound class:
Peptide
Comment: Navepegritide (TransCon CNP) is a prodrug of a human C-type natriuretic peptide (CNP) analogue [1]. It comprises CNP(1-38) attached to an inert polyethylene glycol carrier via a cleavable linker [3]. CNP is a validated therapeutic agent for the treatment of patients with achondroplasia (see the approved CNP analogue vosoritide) [2]. Navepegritide is designed to provide sustained hormone release and continuous CNP exposure as a once-weekly therapy that is proposed to counterbalance the overactivated FGFR3 signaling pathway in achondroplasia [1].
|
| No information available. |
Summary of Clinical Use  |
| Navepegritide (TransCon CNP) has progressed through clinical trials to evaluate safety and efficacy as a treament for the comorbidities associated with achondroplasia. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06079398 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia | Phase 2 Interventional | Ascendis Pharma A/S | ||
| NCT05929807 | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia | Phase 2/Phase 3 Interventional | Ascendis Pharma A/S | ||
| NCT05598320 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia | Phase 2/Phase 3 Interventional | Ascendis Pharma A/S | ||
| NCT04085523 | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia | Phase 2 Interventional | Ascendis Pharma A/S | 3 | |
